Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology (original) (raw)
Fig 3
FACS Analysis of Tumor and Spleen T Cell Populations from MC38 Tumor-Bearing Mice.
MC38 colon tumor cells (2×106) were implanted subcutaneously into female C57BL/6 mice. At day 7 post implantation, tumor-bearing mice were randomized and dosed with 10 mg/kg of antibody IP Q3D×3. On day 15 post implantation, tumors were harvested, dissociated into single-cell suspensions, and stained for flow cytometry. Data are representative of three MC38 independent experiments with ≥5 mice/group/experiment. A-B. Percentages of CD45+ cells that were CD8+ Teffs, CD4+, FoxP3- Teffs, and CD4+ FoxP3+ Tregs found in tumor (A) and matched spleen (B).